Cannabis use and self-reported collisions in a representative sample of adult drivers

Social, Prevention and Health Policy Research, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
Journal of Safety Research (Impact Factor: 1.29). 02/2007; 38(6):669-74. DOI: 10.1016/j.jsr.2007.09.004
Source: PubMed

ABSTRACT This study examines the relationships between collision involvement and several measures of cannabis use, including driving after using cannabis, among drivers, based on a population survey of Ontario adults in 2002 and 2003.
Logistic regression analyses examined self-reported collision involvement in the last 12 months by lifetime use of cannabis, past year use of cannabis, and past year driving after using cannabis, while controlling for demographic characteristics.
We found that the odds of reporting collision involvement was significantly higher among cannabis users, and among those who reported driving after cannabis use. Some evidence for a dose-response relationship was seen as well.
Cannabis users and people who report driving after cannabis use are also more likely to report being involved in a collision in the past year. These observations suggest that collision prevention efforts could be aimed at these groups. Additional work to determine the causal pathways involved in the relationships observed here is needed.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Cannabis use and driving (CUD) is a growing public health concern. This study's main objective was to identify distinguishing characteristics associated with high-frequency CUD (HFCUD) activity (i.e., CUD > 12 times) in a multi-site sample of university students who had self-identified as having driven a car within 4 hours of cannabis use in the past year. Participants for the study (n = 248; age 18-28 years) were recruited by mass advertising at five universities in Ontario. Participants were screened for eligibility and assessed by an anonymous interview between April 2005 and March 2006. Bivariate analyses determined factors associated with HFCUD (i.e., > 12 times) vs. a low frequency of CUD (LFCUD); significant factors were subsequently entered into a discriminant function analysis model. HFCUD was associated with several variables, including frequent (i.e., at least weekly) cannabis use; daily driving; perception of own ability to drive not being impaired by cannabis use; and expectation of CUD in the next 12 months (all p < 0.0001). CUD among young drivers is an important health and safety risk requiring effective interventions. Given the strong association of HFCUD with frequent cannabis use, these phenomena need to be addressed conjointly. Furthermore, preventive interventions responsive to the specific socio-cultural contexts of possible CUD need to be developed and implemented.
    Canadian Journal of Criminology and Criminal Justice 02/2014; 56(2):185-200. DOI:10.3138/cjccj.2014.ES03
  • [Show abstract] [Hide abstract]
    ABSTRACT: Driving under the influence of alcohol or cannabis alone is associated with increased crash risk. This study explores the combined influence of low levels of alcohol (BAC ≤ .08) and cannabis on crash risk.
    Forensic Science International 12/2014; 248C. DOI:10.1016/j.forsciint.2014.12.018 · 2.12 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To offer preliminary guidance on prescribing smoked cannabis for chronic pain before the release of formal guidelines. We reviewed the literature on the analgesic effectiveness of smoked cannabis and the harms of medical and recreational cannabis use. We developed recommendations on indications, contraindications, precautions, and dosing of smoked cannabis, and categorized the recommendations based on levels of evidence. Evidence is mostly level II (well conducted observational studies) and III (expert opinion). Smoked cannabis might be indicated for patients with severe neuropathic pain conditions who have not responded to adequate trials of pharmaceutical cannabinoids and standard analgesics (level II evidence). Smoked cannabis is contraindicated in patients who are 25 years of age or younger (level II evidence); who have a current, past, or strong family history of psychosis (level II evidence); who have a current or past cannabis use disorder (level III evidence); who have a current substance use disorder (level III evidence); who have cardiovascular or respiratory disease (level III evidence); or who are pregnant or planning to become pregnant (level II evidence). It should be used with caution in patients who smoke tobacco (level II evidence), who are at increased risk of cardiovascular disease (level III evidence), who have anxiety or mood disorders (level II evidence), or who are taking higher doses of opioids or benzodiazepines (level III evidence). Cannabis users should be advised not to drive for at least 3 to 4 hours after smoking, for at least 6 hours after oral ingestion, and for at least 8 hours if they experience a subjective "high" (level II evidence). The maximum recommended dose is 1 inhalation 4 times per day (approximately 400 mg per day) of dried cannabis containing 9% delta-9-tetrahydrocannabinol (level III evidence). Physicians should avoid referring patients to "cannabinoid" clinics (level III evidence). Future guidelines should be based on systematic review of the literature on the safety and effectiveness of smoked cannabis. Further research is needed on the effectiveness and long-term safety of smoked cannabis compared with pharmaceutical cannabinoids, opioids, and other standard analgesics. Copyright© the College of Family Physicians of Canada.